Table 3.

Univariate and multivariate Cox proportional hazard analysis of the risk for recurrence as a first event in 82 stage B and 77 stage C colorectal cancer patients, as well as 55 stage C patients with N1 disease for whom confident Prediction Analysis of Microarray class predictions (stage A like/good prognosis or stage D like/poor prognosis) could be made using our 128-gene classifier

PatientsVariableUnivariate analysisMultivariate analysis
Hazard ratio (95% CI)PHazard ratio (95% CI)P
Stage B (n = 82)Classifier (stage D like vs stage A like)10.60 (1.36-82.00)0.0248.55 (1.07-68.61)0.043
Age at diagnosis / 10 y0.83 (0.53-1.29)0.4060.95 (0.54-1.65)0.850
LN examined / 50.74 (0.44-1.24)0.2520.72 (0.40-1.29)0.280
Adjuvant treatment (yes vs no)3.23 (1.04-10.00)0.0425.77 (1.53-21.69)0.010
Stage C (n = 77)Classifier (stage D like vs stage A like)2.85 (1.08-7.53)0.0352.49 (0.90-6.94)0.080
Age at diagnosis / 10 y0.98 (0.75-1.29)0.9030.97 (0.71-1.34)0.870
N stage (2 vs 1)2.18 (1.02-4.66)0.0442.18 (0.91 -5.22)0.079
LN examined / 50.93 (0.76-1.14)0.4950.85 (0.67-1.10)0.210
Adjuvant treatment (yes vs no)0.47 (0.22-1.02)0.0550.34 (0.14-0.80)0.014
Stage C and N1 (n = 55)Classifier (stage D like vs stage A like)3.81 (1.07-13.5)0.0383.67 (1.02-13.21)0.047
Age at diagnosis / 10 y0.99 (0.67-1.46)0.9600.94 (0.60-1.50)0.810
LN examined / 50.91 (0.66-1.27)0.5900.93 (0.66-1.29)0.650
Adjuvant treatment (yes vs no)0.72 (0.25-2.14)0.5650.60 (0.17-2.05)0.410

NOTE: For single-sample Prediction Analysis of Microarray classification, previous (expected) 6-year recurrence probabilities were set as 20% for stage B and 40% for stage C patients based on relapse rates observed in clinical practice (21). Class predictions with a >90% probability were scored. The Ps were calculated using the Wald test.

Abbreviation: LN, lymph node.